Veeda Clinical Research finalized the acquisition of Heads, a prominent European Contract Research Organization (CRO) boasting twenty-five locations across Europe, North America, and the Asia Pacific regions. The move, marks a strategic expansion of Veeda’s global presence.
According to Mahesh Bhalgat, Group CEO, Veeda, the acquisition strategically aligns with the increasing focus on global clinical trials. It enables Veeda to offer access to a diverse population base for efficiently conducting large-scale, multi-geography trials. Heads specializes in managing all stages of clinical trials, particularly catering to biotechnology and pharmaceutical companies focusing on hematology and oncology. Additionally, the acquired CRO provides consulting services for the development of anti-cancer drugs.
As reported by FIERCE Biotech, Veeda’s core operations include preclinical research and comprehensive clinical trial services spanning all phases of clinical development, catering to clients globally, including in the United States. Their services extend to post-marketing surveillance, pharmacovigilance, as well as bioavailability and bioequivalence studies.
